Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 702 (LINC00702)
- Target
- LINC00702
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01
Overview
Long intergenic non-protein coding RNA 702 (LINC00702) is a long non-coding RNA (lncRNA) that does not encode a protein but regulates cellular processes via RNA-based mechanisms. It is notably downregulated in several cancers, including non-small cell lung cancer and gastric cancer, where lower levels are associated with poorer prognosis features such as increased tumor size and metastasis. Mechanistically, LINC00702 acts as a competing endogenous RNA (ceRNA) that sponges miR-510, relieving suppression of the tumor suppressor PTEN and downregulating PI3K-Akt signaling, resulting in suppressed tumor growth, invasion, and increased apoptosis. LINC00702 is of increasing interest as a diagnostic/prognostic biomarker and a potential therapeutic target in oncology
- Other names
- RP11-67B16.1
02
Mechanism of action
Functions as a ceRNA for miR-510, thereby upregulating the tumor suppressor gene PTEN, inhibiting the PI3K-Akt pathway, and suppressing tumor proliferation and metastasis
03
Biological functions
Regulation of cell proliferationRegulation of apoptosisCompeting endogenous RNA (ceRNA) activityRegulation of gene expression (notably modulation of PTEN via miR-510 sponge activity in cancer models)
04
Disease associations
Cancer (notably non-small cell lung cancer, gastric cancer, high-grade serous ovarian cancer)
05
Safety considerations
No specific therapeutic safety issues reported, but general challenges include delivery and off-target effects inherent to RNA-based or gene therapy approaches
06
Interacting drugs
None directly reported (lncRNAs are not directly targeted by small-molecule drugs as of current knowledge, but could be manipulated via nucleic acid therapeutics or indirectly through gene therapy strategies)
07
Biomarkers
Candidate diagnostic and prognostic biomarker in non-small cell lung cancer and possibly gastric and ovarian cancers based on altered expression in tumors vs. normal tissue
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 702 (LINC00702).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 702 (LINC00702).